In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shrnas and by artificial miRNAs

Journal of RNAi and Gene Silencing

Volumn 7, Issue 1, 2011, Pages 434-442

  Borel, Florie ^a,b   van Logtenstein, Richard ^a   Koornneef, Annemart ^a   Maczuga, Piotr ^a,c   Ritsema, Tita ^a   Petry, Harald ^a   van Deventer, Sander J H ^a,c   Jansen, Peter L M ^b   Konstantinova, Pavlina ^a  

^a Amsterdam Molecular Therapeutics ^*  (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aav; Abbc1; Abbc2; Hepatocellular carcinoma; Mirna; Multidrug resistance; Shrna

Indexed keywords

ADENO-ASSOCIATED VIRUS; MUS;

EID: 80053505995     PISSN: 17470854     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cole SP, Sparks KE, Fraser K et al. 1994. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res, 54, 5902-5910.
2. Daya S and Berns KI. 2008. Gene therapy using adenoassociated virus vectors. Clin Microbiol Rev, 21, 583-593.
3. Doege H, Grimm D, Falcon A et al. 2008. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem, 283, 22186-22192.
4. Gao GP, Alvira MR, Wang L et al. 2002. Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA, 99, 11854-11859.
5. Grimm D, Streetz KL, Jopling CL et al. 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 441, 537-541.
6. Grude P, Conti F, Mennecier D et al. 2002. MDR1 gene expression in hepatocellular carcinoma and the peritumoral liver of patients with and without cirrhosis. Cancer Lett, 186, 107-113.
7. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG and Kruh GD. 2004. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res, 64, 4927-4930.
8. Hopper-Borge E, Xu X, Shen T et al. 2009. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res, 69, 178-184.
9. Koornneef A, Maczuga P, van Logtenstein R et al. 2011. Apolipoprotein B Knockdown by AAV-delivered shRNA Lowers Plasma Cholesterol in Mice. Mol Ther, 19, 731-740.
10. Kuppens IE, Witteveen EO, Jewell RC et al. 2007. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res, 13, 3276-3285.
11. Lagas JS, Vlaming ML, Schinkel AH. 2009. Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol Interv, 9, 136-145.
12. Materna V, Stege A, Surowiak P, Priebsch A, Lage H. 2006. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun, 348, 153-157.
13. McBride JL, Boudreau RL, Harper SQ et al. 2008. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA, 105, 5868-5873.
14. McCarty DM, Fu H, Monahan PE et al. 2003. Adeno-associated virus terminal repeat (TR) mutant generates selfcomplementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther, 10, 2112-2118.
15. Mizukoshi E, Honda M, Arai K et al. 2008. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma. J Hepatol, 49, 946-954.
16. Narvaiza I, Aparicio O, Vera M et al. 2006. Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J Virol, 80, 12236-12247.
17. Sledz CA, Holko M, de Veer MJ, Silverman RH, and Williams BR. 2003. Activation of the interferon system by shortinterfering RNAs. Nat Cell Biol, 5, 834-839.
18. Tian Q, Zhang J, Chan SY et al. 2006. Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab, 7, 105-118.
19. Vander BS, Komuta M, Libbrecht L et al. 2008. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int, 28, 1370-1380.
20. Wu Z, Li X, Zeng Y et al. 2011. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin Pharmacol Toxicol, 108, 177-184.
21. Xie SM, Fang WY, Liu Z et al. 2008. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl. Med, 6, 55.
22. Zolotukhin S, Byrne BJ, Mason E et al. 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 6, 973-985.